Opinion

In re ACTOS Antitrust Litigation

Court
District Court, S.D. New York
Filed
May 3, 2023
Cited by
0 cases
Authority
More cited than 27.6%

finding that “[c]onfidential business information dating back even a decade or more may provide valuable insights into a company’s current business practices that a competitor would seek to exploit”

How later courts described this case

  • finding that “[c]onfidential business information dating back even a decade or more may provide valuable insights into a company’s current business practices that a competitor would seek to exploit”

Written by the judges who cited it.

The opinion

e@ —————Oe Os

Morgan Lewis DOCUMENT

ELECTRONICALLY FILED

DOC #:

DATE FILED:__5/3/2023

R. Brendan Fee

Partner

+1.215.963.5136

brendan.fee@morganlewis.com

May 2, 2023

VIA ECF Application GRANTED. For the reasons set forth herein,

The Honorable Stewart D. Aaron the Court finds that the proposed redactions are

narrowly tailored to prevent the dissemination of

United States District Court a: tae .

□□ competitively sensitive information. SO ORDERED.

Southern District of New York Dated: Mav 3, 2023

Daniel Patrick Moynihan aregemey © At Cf Gn

United States Courthouse

500 Pearl Street

New York, NY 10007-1312

Re: Supplemental Letter Motion to Seal — Jn re ACTOS Antitrust Litig. (1:13-cv-

09244-RA-SDA)

Dear Judge Aaron:

Pursuant to Your Honor’s Order that Takeda “make a further application in support of” its

motion to seal information in Plaintiffs’ Reply Brief in Support of Letter Motion for

Discovery Conference Concerning Depositions (ECF No. 508), Takeda submits this letter

in further support of sealing certain information that is currently redacted.

Although “[t]he common law right of public access to judicial documents is firmly rooted

in our nation’s history,” this right is not absolute and courts “must balance competing

considerations against” the presumption of access. Lugosch v. Pyramid Co. of Onondaga,

435 F.3d 110, 119-20 (2d Cir. 2006). Such competing considerations include the “need to

protect sensitive commercial information from disclosure to competitors seeking an

advantage.” Johnson v. Tennyson, No. 22-CV-05683 (SDA), 2023 WL 2423965, at *1

(S.D.N.Y. Mar. 9, 2023) (Aaron, J.) (quoting /n re Keurig Green Mountain Single-Serve

Coffee Antitrust Litig., No. 14-MC-02542 (VSB), 2014 WL 12772236, at *2 (S.D.N.Y.

Nov. 5, 2014)). If competing considerations outweigh the presumption of access, the

sealing of information should be narrowly tailored. Lugosch, 435 F.3d at 126.

Here, after additional careful review of the information currently redacted, Takeda requests

that the Court maintain under seal only the information in the two parentheticals in the first

paragraph of page 8 of Ex. N (ECF No. 489-2) regarding a settlement term that Takeda

Morgan, Lewis & Bockius LLP

1701 Market Street

Philadelphia, PA 19103-2921 © +1.215.963.5000

United States @ +1.215.963.5001

was considering as part of the Actos patent litigations. These parentheticals reveal

competitively sensitive information about Takeda’s past practices and strategies for

settling patent infringement lawsuits against generic manufacturers seeking to market

generic versions of Takeda’s patented branded products. See Encyclopedia Brown Prods.,

Ltd. v. Home Box Off., Inc., 26 F. Supp. 2d 606, 614 (S.D.N.Y. 1998) (finding that

“[c]onfidential business information dating back even a decade or more may provide

valuable insights into a company’s current business practices that a competitor would seek

to exploit”). If made public, this information could be used to Takeda’s detriment in

current and future settlement negotiations. These proposed redactions are narrowly

tailored to prevent the dissemination of this competitively sensitive information and to

avoid future injury to Takeda.

We appreciate Your Honor’s consideration of this matter.

Respectfully submitted,

/s/ R. Brendan Fee

R.Brendan Fee

Attorney for Defendants Takeda Pharmaceutical

Company Limited, Takeda America Holdings,

Inc., Takeda Pharmaceuticals U.S.A., Inc., and

Takeda Development Center Americas, Inc.

This is a copy of a public record, reproduced as it was published. It is not legal advice, and it may not be the version a court would rely on. Check the official source before you cite it.

A word about cookies

We need a few to keep you signed in and the library working. The rest help us see which pages people use and where they get stuck. They stay off unless you say yes.